管理層發言
Good morning, and welcome to the Amneal Pharmaceuticals Second Quarter 2026 Earnings Call. I will now turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.
Good morning, and thank you for joining Amneal Pharmaceuticals second quarter 2026 earnings call. Today, we issued a press release reporting Q2 results. The earnings press release and presentation are available on the IR page of amneal.com. Certain statements made on this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please see the sections entitled Cautionary Statements on Forward-Looking Statements in our press release and presentation for factors that may impact future performance. We also discuss non-GAAP measures. Information on use of these measures and reconciliations to GAAP are in the earnings release and presentation. On the call today are Chirag and Chintu Patel, Co-Founders and Co-CEOs; Tasos Konidaris, CFO; Joe Renda for Specialty; and Jason Daly, Chief Legal Officer. I will now hand the call over to Chirag.
Thank you. Good morning, everyone. Amneal is in the midst of the most transformative period in our company's history. We are growing as one of America's leading Affordable Medicines businesses with an increasingly diversified and high-impact medicines portfolio, including Specialty brands, biosimilars, GLP-1s and complex generics across dosage forms such as transdermals and injectables. As we execute our strategy, we are building a larger, more impactful Amneal. That continued momentum is reflected in our second quarter results, where the company delivered revenue of $796 million, adjusted EBITDA of $206 million and adjusted EPS of $0.30. At the halfway point of the year, we are pleased to once again raise our 2026 outlook. This year reflects our seventh consecutive year of top and bottom line growth. As a purpose-driven company, we have a tremendous opportunity to help the next era of Affordable Medicines here in the United States and globally by expanding access for patients and providers. While Amneal has always been growth-oriented, the scale of the opportunity in front of us today has never been greater. With that, let me touch on key growth opportunities. First, in Affordable Medicines, our base business remains strong, resilient and growing with highly relevant and in-demand therapies. In Women's Health, demand for transdermal patches increased following the revised FDA guidance late last year. We are increasing our capacity. Looking forward, our pipeline remains focused on high-value opportunities such as lanreotide where complexity, reliable supply, customer relationship and execution are key. Second, in biosimilars, we're building a new large growth platform for Amneal. With the pending acquisition of Kashiv, we would become a fully integrated global biosimilar player from development to commercial supply. And the timing is incredibly compelling. The U.S. biosimilars market is entering a major growth cycle driven by an unprecedented wave of biologics losing exclusivity, streamlined regulatory pathways, attractive commercial structures emerging, including private labels and accelerating market adoption. Over the next decade, 118 biologics are expected to lose exclusivity in the United States alone, with relatively limited development expected for most molecules. Accordingly, we see a broad set of biosimilar opportunities with limited competition that can support reliable and repeatable value creation. Amneal is well positioned to capitalize on these opportunities. Approximately 75% of our biosimilar portfolio will be focused on targeted lower competition while 25% will address larger market opportunities. That mix gives us significant growth potential and meaningful upside. Biosimilars align with our commercial strength as well. Through private label and customer relationships, we can bring products to market efficiently, leveraging our leading U.S. retail and institutional presence, channel access and scale. This is a national extension of our Affordable Medicines strategy. Overall, biosimilars are the next major growth area for Amneal and fit directly in our mission, expanding access, providing affordability and building a durable long-term growth platform. Third, in Specialty, we have a differentiated branded product portfolio. CREXONT continues to gain traction and recent Phase IV data reinforces its potential to become a first-line treatment option for Parkinson's patients. Also, BREKIYA continues to see very strong uptake in its first several quarters on the market as it addresses an important unmet need for migraine and cluster headache sufferers. Fourth, in distribution, AvKARE continues to provide diversification and access to important government and institutional channels, representing a meaningful opportunity to grow this business over time. In summary, we are incredibly excited about the ongoing strategic evolution of Amneal and highly confident in our ability to sustain this momentum going forward. I'll now turn it over to Chintu.
Thank you, Chirag, and good morning, everyone. I would like to thank our Amneal team for another quarter of very strong execution. Our team continues to deliver across operations, quality, supply chain, R&D, commercial execution and customer service. This consistency allows us to grow while also building towards the next generation of opportunities such as Specialty, biosimilars and GLP-1s. Let me begin with an update on one of our manufacturing sites in India. One week ago, the Gujarat region experienced severe rainfall and flooding, which impacted one of our facilities in India. Most importantly, all Amneal employees are safe and accounted for. We expect a limited impact on a select number of products. We look to resume operation within the next few weeks. I will provide an update on three areas: first, the strength of our operating platform; second, the strategic fit and capabilities Kashiv brings in biosimilars; and third, the continued momentum across our pipeline. First, in operation, our global high-quality manufacturing and supply chain capabilities remain a core competitive advantage. If you walk into an Amneal facility today, it looks remarkably different than just several years ago. Through digitization, automation and deploying AI tools in different areas, we are unveiling our next generation of manufacturing and quality while also driving continued efficiencies. Strategically, we have built a broad operational network with deep expertise across dosage forms. This matters more than ever. Patients, providers and all stakeholders of the health care system are focused on the quality, reliability and resiliency of the pharmaceutical supply chain. We are excited to expand our capabilities and capacity in complex dosage forms, including transdermals, sterile injectables and long-acting depots, enabling Amneal to increase our volumes and drive very meaningful near-term growth. Our scale, leading U.S. manufacturing footprint and strong technical capabilities position us to deliver reliable, high-quality supply while addressing important market needs and drug shortages. To that point, we are pleased to share that Amneal's Brookhaven, New York site was recently selected as one of only seven companies in the FDA's PreCheck Pilot Program, alongside other leading companies such as Eli Lilly and Regeneron. The program is intended to advance U.S. drug manufacturing and strengthen supply chain resiliency by allowing earlier FDA engagement on facility readiness and support access to critical medicine. For Amneal, it is an important recognition of our robust U.S. manufacturing, particularly as we expand into sterile injectable manufacturing here in the U.S. over the next few years. Second, we are very excited about the Kashiv acquisition, which will add the in-house biologics capabilities we need to succeed in biosimilars. The end-to-end capabilities will span cell line and clone development, protein characterization, process development, clinical execution, regulatory expertise and scaled biologics manufacturing in India and the U.S. Kashiv is a biologics platform built over a decade with deep scientific expertise across monoclonal antibodies, fusion proteins, cytokines, microbial products and other complex modalities. Kashiv's drug substance capacity is expected to expand from approximately 26,000 liters by the end of 2026 to approximately 75,000 liters by 2028. With Kashiv, we will be able to do it all in biologics. Kashiv brings the science, development and manufacturing engine and Amneal brings the U.S. commercial engine with our leading retail position and channel expertise. This is a powerful combination. Together, this combined model will allow us to advance multiple molecules at the same time, make smart portfolio decisions, move quickly and capture more economics across the value chain. With our current and future biosimilar capacity, we are well positioned to supply a meaningful share at launch with excess capacity to respond to market demand as needed. In addition, the combined pipeline of over 20 biosimilar programs supports a meaningful number of new launches over time. We are very excited about upcoming biosimilar opportunities for XOLAIR, ORENCIA, CIMZIA and Nplate, which are attractive molecules with significant market potential and relatively limited competition. We believe each has the potential to become a meaningful growth driver. Longer term, the pipeline extends well into the 2030s, providing substantial runway for growth. Third, turning to our Affordable Medicines pipeline. We are in the midst of the most concentrated and impactful wave of high-value new launches in our company's history. Importantly, it is not just the number of launches that matters, it is the value, complexity and durability of these products. This momentum is the result of choices we made many years ago. We deliberately prioritized complex generics and differentiated dosage forms, including injectables, ophthalmics, inhalation products, drug-device combinations, 505(b)(2) opportunities and other non-oral solid dosage forms, where technical complexity and execution create long-term durable value. Our recent approvals and upcoming launches show the strategy is working. This includes the recent approval of romidepsin in oncology, additional strengths of presentation of iohexol and ready-to-use sodium bicarbonate, our latest 505(b)(2) injectables, along with potential approval of lanreotide in Q3. Each product reflects the high-impact opportunities that we have been building towards and demonstrate the strength of our Affordable Medicines pipeline. And the wheel of innovation continues to turn with another 12 to 15 high-value complex ANDA filings planned this year, including two more metered-dose inhalation products. These opportunities exemplify Amneal's core strength, strong R&D, complex manufacturing, deep customer relationships and a track record of reliable supply. We are using the same playbook that built our Affordable Medicines business and applying it to biosimilars. In Specialty, we are pleased with the continued strong performance of CREXONT and BREKIYA. These successful product launches reflect our ability to develop new medicines, build brands and bring forward therapies that improve patient care. For CREXONT, the real-world evidence for Parkinson's patients is very compelling. We recently shared data from our first Phase IV open-label study that showed patients converting to CREXONT had three or more hours of "Good on" time per day versus RYTARY and other carbidopa/levodopa therapies and a meaningful improvement in symptom control. In Q4, we are starting a new Phase IV study looking at the impact of CREXONT on treatment-naive patients recently diagnosed with Parkinson's disease and disease progression. More broadly, we are building on this Specialty foundation with additional R&D pipeline opportunities. While CREXONT and BREKIYA are key growth drivers today, they represent the beginning of a broader Specialty pipeline that we are advancing and we look to share more in the future. Taken together, we are well positioned for continued growth and remain laser-focused on executing across our key operational, commercial and pipeline opportunities. I will now hand it over to Tasos.
Thank you, Chintu, and good morning, everyone. The second quarter played out as expected with revenue growth accelerating and broad-based momentum building across our business. Consequently, we are very pleased with our continued strong financial performance and ability to raise our 2026 outlook again this quarter, reflecting the strength and diversification of our business, a number of key growth drivers and the success of the business model we have strategically built over several years. We expect this momentum to continue through the balance of 2026 and into 2027 and beyond. For the second quarter, total net revenue was $796 million, up 10%. Adjusted EBITDA was $206 million, up 12%, and adjusted EPS was $0.30, up 20%. Our results were driven by strong execution across our three business segments, favorable product mix and operating expense discipline. In the second quarter, Affordable Medicines delivered revenue of $490 million, up 13%, reflecting the strength of our broad-based complex portfolio, including our Women's Health products, injectables and higher naloxone sales. In addition, new product launches added $45 million to second quarter revenue growth, including two recently launched products, one in ophthalmology and one in urology. Our Specialty revenue was $149 million, up 17%, driven by continued momentum in CREXONT, UNITHROID and BREKIYA, all ahead of expectations. Moving on to AvKARE, where second quarter revenue was $157 million, down 4%, similar to the first quarter as growth in the government channel was offset by the low-margin distribution business as we expected. As we have said in the past, we remain focused on the unique value we provide in the government channel and continue to expand AvKARE's profitability. Moving down the P&L, our second quarter adjusted gross margin was strong at 46.2%, up 60 basis points year-over-year, reflecting favorable mix and continued operating efficiencies. Adjusted EBITDA grew 12% due to strong revenue growth, gross margin expansion and disciplined expense management. From an adjusted EPS perspective, the second quarter grew 20%, reflecting the adjusted EBITDA growth and lower interest expense. Let me take a moment to acknowledge the strength of our first half financial performance with total revenues up 7%, adjusted EBITDA up 16%, and adjusted EPS growth of 27%. Furthermore, I'm pleased to report that we recently repriced our $2.084 billion Term Loan B due in 2032 and reduced our interest expense by 50 basis points, which equates to $12 million in annual interest expense savings. Given the strength of our business, we're very pleased to raise our full year 2026 guidance this quarter. We're increasing our revenue outlook by $50 million to $3.1 billion to $3.2 billion with high single-digit growth expected in both Specialty and Affordable Medicines. Also, we're raising our adjusted EBITDA guidance by $10 million to between $750 million and $780 million, reflecting strong revenues and higher gross margin. This guidance includes an estimated $20 million of negative impact anticipated as a result of the recent flood in our India facility, as Chintu mentioned earlier. From an EPS perspective, we're increasing our guidance by $0.01 to between $0.96 and $1.06 due to our higher profitability and lower interest expense following our most recent successful debt repricing. From a CapEx perspective, we're increasing our expectations from about $110 million to about $150 million to capitalize on multiple near-term opportunities that we see in the marketplace, such as greater market demand for our Women's Health products and injectable expansion in the U.S. Finally, we're maintaining our operating cash flow guidance. Turning to Kashiv for a second. We're entering the transaction from a position of strength, supported by a diverse set of growth drivers, strong cash flow and disciplined balance sheet management. This progress was further validated in April when we received a one-notch credit rating upgrade in our most recent successful Term Loan B repricing. As we have outlined, the Kashiv transaction is compelling both strategically and financially. First, the acquisition enables us to be a leader in the multibillion-dollar global biosimilars market that is growing rapidly. Second, we expect to capture $400 million to $500 million in financial benefits driven by tax and local incentives as well as eliminating milestone and profit-sharing obligations. Third, we see a clear path to deleveraging with net leverage below 3x by 2028. We expect the Kashiv transaction to close over the next few weeks, pending shareholder vote tomorrow and satisfaction of closing conditions. With that, I will turn the call back to Chirag.
Thank you, Tasos. Our Q2 results demonstrate the strength of Amneal's diversified business and the momentum across our growth platforms. We are delivering strong performance today with more significant opportunities ahead than any point in our company's history. The pending Kashiv acquisition is a natural extension of our strategy that will create a fully integrated global biosimilar platform, provide us access to a very large market opportunity and establish a major new long-term growth pillar. We are excited about the future and the substantial value creation ahead. Our goal remains clear to become America's #1 Affordable Medicines company and a leading global provider of essential medicines because innovation only matters when it reaches the patient. With that, let's open the call for Q&A.
分析師問答
Operator Instructions: To ask a question, please press *1.
Yes, just two quick ones for me. Chirag, I think I heard you say you're still expecting the timing for lanreotide to be Q3. And if memory serves me correct, the biosimilar for XOLAIR, you're expecting later in the fourth quarter. So I'm just kind of curious as to maybe what you have included in your second half fiscal '26 guide for these launches? And then my second question is really around Kashiv. I think at the time of the deal, you said you're expecting to have six commercial biosimilars in the market by 2027 with a $14 billion TAM. I was just wondering if you could give us more of an update on the timing and maybe a little bit more transparency into which launches will be more meaningful here?
So, lanreotide is on its way. That's what we feel as of today. It has an official goal date in Q3. So we have included some of the forecast number, but not probably the full market. Conservative assumptions are included. And XOLAIR is towards the very late end of the year or could spill into January 5. So nothing is included for XOLAIR for this year. Regarding Kashiv BioSciences and your question on the six commercial biosimilars, as you know, we market ALYMSYS, RELEUKO, FYLNETRA. We are launching Prolia and XGEVA and look forward to launching XOLAIR sometime next year, hopefully very early. So that becomes the six biosimilars commercialized by next year and more to follow in '27, '28, '29 — a very exciting pipeline.
Very conservative on that.
Your next question comes from Chris Scott with JPMorgan.
This is Ekaterina on for Chris. Just two questions from us. First, on tariffs — your thoughts on some of these recent headlines from the administration. How should we think about potential impact both for Amneal and the industry? Have there been any discussions between generic manufacturers and the administration since the announcement? And then second, on CREXONT. It seems like another very strong quarter for the product. Any interesting trends you guys are seeing in terms of where uptake is coming from or anything else you're kind of seeing in that market?
As you know, Amneal has a very vast manufacturing network in the United States. We are also expanding our capacity in the United States in sterile injectables and patches as well. As far as the recent announcement, we look forward to more information and we'll collaborate with the administration as we move forward. On your second question about CREXONT, we're seeing 80% of the scripts coming from general neurologists, which wasn't the case for RYTARY, and that continues to happen. As you know, 80% of prescriptions are written by general neurologists. So that is very exciting. The Phase IV data is exciting as well and was well received, and the script trend keeps going up every week. It's truly a needed therapy for Parkinson's patients, and our goal will be to make that a first-line therapy replacing immediate-release products.
Your next question comes from David Amsellem from Piper Sandler.
A couple for me. First on iohexol with the additional SKUs approved, can you talk about how big of an opportunity that could be, not just this year, but also in '27, if you can quantify that and your views on how long that could be a situation where there's limited competition? And a similar question on lanreotide. If you get approved, how long could that be a limited competition situation? And then lastly, on your Specialty business and particularly neurology, what's your appetite for adding assets where you can leverage your existing commercial infrastructure in neurology?
Iohexol is a very complex product, and it requires very good supply chain control and a manufacturing footprint. We are very excited with the new SKUs that are getting approved. We are expecting one or two more strengths to get approved by the end of the year. I think going into next year, we'll complete the entire basket because it has multiple strengths. At the same time, we have increased our capacity this year, and we look forward to capitalizing on the full market potential next year. From a quantification perspective, we think this is a $50-plus million opportunity, maybe more going forward, and we have secured a very good supply chain. Regarding lanreotide, it's the same thing. It's a very complex manufacturing product. As you know, it's a drug-device combination; it's a peptide; it's a very unique formulation. So it has many barriers to entry. We have a dedicated site and facility. We are controlling our in-house supply chain. So we are very positive and optimistic about staying a market leader upon the launch in Q3 as anticipated. We have inventory to go and have perfected the manufacturing. So we look forward to the lanreotide launch in Q3 of this year.
Great. I'll take the second one on the Specialty M&A potential. As we have stated before, the company's focus and goal will turn to the Specialty side starting next year and for many years to come after that. We have a full mass and great infrastructure for small molecule and large molecule with the pending Kashiv acquisition. So we'll keep investing in our internal growth, R&D and CapEx for Affordable Medicines and we will not take our eyes off that business. It's a great business. The existing business is growing remarkably with new pipeline launches, Women's Health, lidocaine expansion, and injectable expansion in the United States. We could not even supply more in some cases. That is a very positive sign. Generics are still highly utilized and complex products often face shortages, and we are there to support that. We are excited about biosimilars and have enough capacity and will keep expanding with CapEx. With excess cash and other means, we would be focusing on CNS assets. Our team is looking at that. We are also looking at oncology assets. We'll be adding a pipeline internally and externally, and we'll share with you when we are ready.
Your next question comes from Ash Verma with UBS.
Congrats on the progress here. I had two questions on individual products. On lanreotide, you've been reiterating Q3 as an approval and launch. Help us understand if there could be any gating items from the FDA side on granting the approval? Have you had any late-cycle review meetings recently? Any back-and-forth with the FDA you can talk about? And then on iohexol, you're building out the SKU portfolio. Is adoption of iohexol contingent on having all the SKUs? Or can we start to see meaningful revenue contribution from what you have right now and then build out from later dosing after that? Any comment would be helpful.
On lanreotide, we responded to all the FDA queries with a very comprehensive response. We are very optimistic. As of today, we haven't had any negative feedback from the FDA. So we believe no news is good news. It is under priority review, as FDA understands it's an unmet need. So we remain very, very optimistic about a Q3 approval and launch, and we have inventory ready to go upon approval. On iohexol, our strategy was to get all the SKUs together. Our R&D has completed all the work. It's not necessary to have all the SKUs to start, but we took a strategic position so that we can capture a bigger share of the market and we are expanding capacity. So in 2026, iohexol does not have meaningful revenue, but from 2027 onwards, it will add substantial revenue growth.
Your next question comes from Matt Dellatorre with Goldman Sachs.
Congrats on the strong quarter. Chirag, you kicked off the call highlighting how Amneal is in the most transformative period in the company's history. The two big things that come to mind are the recent biosimilars integration and the Pfizer GLP-1 partnership. I know you discussed the biosimilar side a bit, but walk us through what you're most focused on with respect to both of these programs over the next six to twelve months. And what would you highlight beyond these programs that you're paying attention to? And on the Affordable Medicines side, you guys have highlighted a significant pickup in demand for estrogen patches post the recent black box removal. Walk us through how large that market potential is and how much Amneal is positioned to capture.
Great. I'll start with Affordable Medicines and the existing business. We are very excited. We used to have this kind of excitement from 2010 to 2018, and those times have come back. Two reasons: the existing products and huge demand for patches, including estrogen patches, and we make them in New Jersey and expansion is underway 24/7. Our teams worked with the equipment supplier to bring the equipment earlier, and we look to triple capacity by next year. So it's a huge addition in revenue. Also, we are expanding lidocaine which is also in shortage. So demand is going up as well for both patches and lidocaine patches. With patches, ophthalmics in high demand, regular products being in high demand and new product launches, Affordable Medicines could add — it's a wide range — but it could add $1 billion to $2 billion of new revenue from now to 2030. We are excited about the existing pipeline, new product launches and the in-line products. On biosimilars, we've spoken enough: a huge growth opportunity. In Specialty, CREXONT keeps expanding, BREKIYA is breaking records and UNITHROID is steady growth. We expect these three brands to continue to grow. On top of that, the organic pipeline would be revealed probably in the first quarter next year. We will also look to be active in partnerships and acquisitions of branded products that fit our commercial infrastructure and categories, and we may add oncology assets as well, since we have the biosimilar oncology team already and more market knowledge over the last three years. On GLP-1 peptides, Pfizer's results are good in clinical trials and our partnership is moving extremely well. Both plants are coming up as fast as they can and should be operational in 2029 and 2030, and we look to start supplying in 2030. We have evaluated markets where we have exclusive commercial rights like India and Egypt, and those look good as well. This is an exciting opportunity. The large infrastructure also opens up additional manufacturing of peptides and finished products for other branded companies or future generic products.
On biosimilars, in the next six to twelve months we are very much focused on integrating Kashiv and advancing our pipeline on abatacept, Nplate and CIMZIA. R&D will be key, and that's where Amneal has always shined. Enhanced R&D capabilities will allow us to file three or four biosimilars a year, which is potentially possible. Entering biologics also opens up different platforms within biologics and potential drug-device combination opportunities to create differentiated biosimilar-like products. We are focused on biosimilars — there are plenty of products to advance in our pipeline and infrastructure.
Yes, I think we answered.
We have reached the end of the Q&A session. I will now turn the call back to Co-CEO, Chirag Patel, for closing remarks.
Well, thank you very much, everybody, and have a great Thursday. Take care.
This concludes today's call. Thank you for attending. You may now disconnect.